Animal models in the drug discovery pipeline for Alzheimer's disease

British Journal of Pharmacology

Volumn 164, Issue 4, 2011, Pages 1285-1300

  Van Dam, Debby ^a   De Deyn, Peter Paul ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

Alzheimer's disease; amyloid ; Caenorhabditis elegans; Drosophila melanogaster; lesion models; rodent models; tauopathy; transgenesis; translational research; zebrafish

Indexed keywords

8 QUINOLINOL DERIVATIVE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; BETA SECRETASE 1; CHOLINESTERASE; CURCUMIN; CX 217; DNA; DONEPEZIL; GLUTAMATE RECEPTOR ANTAGONIST; IBOTENIC ACID; IBUPROFEN; IMMUNOGLOBULIN; INOSITOL; KAINIC ACID; LITHIUM CARBONATE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; QUINOLINIC ACID; QUISQUALIC ACID; RALOXIFENE; RIVASTIGMINE; SAPORIN; SCOPOLAMINE; SEMAGACESTAT; SIMVASTATIN; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; CAENORHABDITIS ELEGANS; CAT; CHOLINERGIC NERVE CELL; COGNITION; DISEASE MODEL; DNA MODIFICATION; DOG; DOSAGE SCHEDULE COMPARISON; DROSOPHILA MELANOGASTER; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; GOAT; HUMAN; NERVE CELL DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHENOTYPE; POLAR BEAR; PRIMATE; PRIORITY JOURNAL; REVIEW; RODENT; SENESCENCE ACCELERATED MOUSE; SHEEP; SINGLE DRUG DOSE; SPECIES DIFFERENCE; TRANSGENIC ANIMAL; TRANSLATIONAL RESEARCH; WOLF; ZEBRA FISH;

ALZHEIMER DISEASE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DEMENTIA; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; MICE; MODELS, GENETIC; RATS;

EID: 80051544073     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01299.x     Document Type: Review

References (173)

1. Adlard, PA, Cherny, RA, Finkelstein, DI, Gautier, E, Robb, E, Cortes, M, et al,. (2008). Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59: 43-55. (Pubitemid 351905863)
2. Ahmed T, Gilani AH, (2009). Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav 91: 554-559.
3. Ahmed T, Enam SA, Gilani AH, (2010). Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer's disease. Neuroscience 169: 1296-1306.
4. Ali AK, Banks WA, Kumar VB, Shah GN, Lynch JL, Farr SA, et al,. (2009). Nitric oxide activity and isoenzyme expression in the senescence-accelerated mouse p8 model of Alzheimer's disease: effects of anti-amyloid antibody and antisense treatments. J Gerontol A Biol Sci Med Sci 64: 1025-1030.
5. Alonso JR, U HS, Amaral DG, (1996). Cholinergic innervation of the primate hippocampal formation: II. Effects of fimbria/fornix transection. J Comp Neurol 375: 527-551. (Pubitemid 26398340)
6. Amsterdam A, Hopkins N, (2006). Mutagenesis strategies in zebrafish for identifying genes involved in development and disease. Trends Genet 22: 473-478. (Pubitemid 44233717)
7. Arslanova D, Yang T, Xu X, Wong ST, Augelli-Szafran CE, Xia W, (2010). Phenotypic analysis of images of zebrafish treated with Alzheimer's gamma-secretase inhibitors. BMC Biotechnol 10: 24.
8. Bai Q, Garver JA, Hukriede NA, Burton EA, (2007). Generation of a transgenic zebrafish model of tauopathy using a novel promoter element derived from the zebrafish eno2 gene. Nucleic Acids Res 35: 6501-6516. (Pubitemid 350111618)
9. Banks WA, Farr SA, Butt W, Kumar VB, Franko MW, Morley JE, (2001). Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. J Pharmacol Exp Ther 297: 1113-1121. (Pubitemid 32472511)
10. Basak JM, Holtzman DM, (2010). APP-based transgenic models of Alzheimer's dementia: the PDAPP Model. In:, De Deyn PP, Van Dam D, (eds). Animal Models of Dementia. Springer Science + Business Media: New York, pp. 371-385.
11. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, et al,. (1995). Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 64: 749-760.
12. Bill BR, Petzold AM, Clark KJ, Schimmenti LA, Ekker SC, (2009). A primer for morpholino use in zebrafish. Zebrafish 6: 69-77.
13. Boimel M, Grigoriadis N, Lourbopoulos A, Touloumi O, Rosenmann D, Abramsky O, et al,. (2009). Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J Neuropathol Exp Neurol 68: 314-325.
14. Bons N, Mestre N, Ritchie K, Petter A, Podlisny M, Selkoe D, (1994). Identification of amyloid beta protein in the brain of the small, short-lived lemurian primate Microcebus murinus. Neurobiol Aging 15: 215-220.
15. Braak H, Braak E, Strothjohann M, (1994). Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat. Neurosci Lett 171: 1-4. (Pubitemid 24142074)
16. Brenner S, (1974). The genetics of Caenorhabditis elegans. Genetics 77: 71-94.
17. Butterfield DA, Poon HF, (2005). The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Exp Gerontol 40: 774-783. (Pubitemid 41416540)
18. Byerly L, Cassada RC, Russell RL, (1976). The life cycle of the nematode Caenorhabditis elegans. I. Wild-type growth and reproduction. Dev Biol 51: 23-33.
19. Campbell WA, Yang H, Zetterberg H, Baulac S, Sears JA, Liu T, et al,. (2006). Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss. J Neurochem 96: 1423-1440.
20. Castañé A, Theobald DE, Robbins TW, (2010). Selective lesions of the dorsomedial striatum impair serial spatial reversal learning in rats. Behav Brain Res 210: 74-83.
21. Conlon RA, (2010). Transgenic and gene targeted models of dementia. In:, De Deyn PP, Van Dam D, (eds). Animal Models of Dementia. Springer Science + Business Media: New York, pp. 77-90.
22. Cork LC, Powers RE, Selkoe DJ, Davies P, Geyer JJ, Price DL, (1988). Neurofibrillary tangles and senile plaques in aged bears. J Neuropathol Exp Neurol 47: 629-641.
23. Cotman CW, Head E, (2008). The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J Alzheimers Dis 15: 685-707.
24. Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA, et al,. (2005). Intraneuronal Ab, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 132: 123-135. (Pubitemid 40380720)
25. Cummings BJ, Su JH, Cotman CW, White R, Russell MJ, (1993). Beta-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer's disease. Neurobiol Aging 14: 547-560.
26. Cummings BJ, Head E, Ruehl W, Milgram NW, Cotman CW, (1996). The canine as an animal model of human aging and dementia. Neurobiol Aging 17: 259-268. (Pubitemid 26167637)
27. Daigle I, Li C, (1993). apl-1, a Caenorhabditis elegans gene encoding a protein related to the human beta-amyloid protein precursor. Proc Natl Acad Sci U S A 90: 12045-12049.
28. Davies P, Maloney AJ, (1976). Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403. (Pubitemid 8004505)
29. De Deyn PP, Van Dam D, (eds). (2010a). Animal models of dementia. Neuromethods, Vol. 48, 1st edn. Springer Science + Business Media: New York.
30. De Deyn PP, Van Dam D, (2010b). Dementia and related disorders. In:, Stolerman IP, (ed.). Encyclopedia of Psychopharmacology. Springer Science + Business Media: New York, pp. 383-388.
31. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, et al,. for the Alzheimer's Disease Neuroimaging Initiative (2010). Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67: 949-956.
32. Deacon RMJ, (2010). APP-based transgenic models of Alzheimer dementia: the Tg2576 mouse. In:, De Deyn PP, Van Dam D, (eds). Animal Models of Dementia. Springer Science + Business Media: New York, pp. 387-398.
33. Dournaud P, Delaere P, Hauw JJ, Epelbaum J, (1995). Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer's disease. Neurobiol Aging 16: 817-823.
34. Ebert U, Kirch W, (1998). Scopolamine models of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 28: 944-949. (Pubitemid 28521587)
35. Erickson CA, Barnes CA, (2003). The neurobiology of memory changes in normal aging. Exp Gerontol 38: 61-69. (Pubitemid 36110499)
36. Estapé N, Steckler T, (2002). Cholinergic blockade impairs performance in operant DNMTP in two inbred strains of mice. Pharmacol Biochem Behav 72: 319-334. (Pubitemid 34251342)
37. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, et al,. (2003). The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 84: 1173-1183. (Pubitemid 36330669)
38. Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M, (2004). A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster. Mol Cell Neurosci 26: 365-375. (Pubitemid 38968431)
39. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC, (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811. (Pubitemid 28099681)
40. Frautschy SA, Yang F, Calderon L, Cole GM, (1996). Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits. Neurobiol Aging 17: 311-321. (Pubitemid 26167642)
41. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al,. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373: 523-527.
42. Gearing M, Rebeck GW, Hyman BT, Tigges J, Mirra SS, (1994). Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer's disease. Proc Natl Acad Sci U S A 91: 9382-9386. (Pubitemid 24297918)
43. Gearing M, Tigges J, Mori H, Mirra SS, (1997). β-amyloid (Aβ) deposition in the brains of aged orangutans. Neurobiol Aging 18: 139-146. (Pubitemid 27355931)
44. Geerts H, (2009). Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs 23: 915-926.
45. Geerts H, (2010). Pharmacological validation in animal models of dementia. In:, De Deyn PP, Van Dam D, (eds). Animal Models of Dementia. Springer Science + Business Media: New York, pp. 155-168.
46. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al,. (2007). Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 28: 537-547. (Pubitemid 46282205)
47. Geula C, Nagykery N, Wu CK, (2002). Amyloid-beta deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): incidence and chemical composition. Acta Neuropathol 103: 48-58. (Pubitemid 36075312)
48. Giannakou ME, Crowther DC, (2010). Drosophila melanogaster as a model organism for dementia. In:, De Deyn PP, Van Dam D, (eds). Animal Models of Dementia. Springer Science + Business Media: New York, pp. 223-240.
49. Glenn MJ, Nesbitt C, Mumby DG, (2003). Perirhinal cortex lesions produce variable patterns of retrograde amnesia in rats. Behav Brain Res 41: 183-193. (Pubitemid 36542966)
50. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al,. (2003). Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100: 10417-10422. (Pubitemid 37071893)
51. Götz J, Schild A, Hoerndli F, Pennanen L, (2004). Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci 22: 453-465. (Pubitemid 39311434)
52. Gray JA, McNaughton N, (1983). Comparison between the behavioural effects of septal and hippocampal lesions: a review. Neurosci Biobehav Rev 7: 119-188. (Pubitemid 13099760)
53. Greeve I, Kretzschmar D, Tschäpe JA, Beyn A, Brellinger C, Schweizer M, et al,. (2004). Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci 24: 3899-3906. (Pubitemid 38544216)
54. Groth C, Nornes S, McCarty R, Tamme R, Lardelli M, (2002). Identification of a second presenilin gene in zebrafish with similarity to the human Alzheimer's disease gene presenilin2. Dev Genes Evol 212: 486-490. (Pubitemid 36067689)
55. Gunn-Moore DA, McVee J, Bradshaw JM, Pearson GR, Head E, Gunn-Moore FJ, (2006). Ageing changes in cat brains demonstrated by beta-amyloid and AT8-immunoreactive phosphorylated tau deposits. J Feline Med Surg 8: 234-242. (Pubitemid 44063373)
56. Hampson RE, España RA, Rogers GA, Porrino LJ, Deadwyler SA, (2009). Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717. Psychopharmacology 202: 355-369.
57. Hardy J, Selkoe DJ, (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356. (Pubitemid 34790756)
58. Harkany T, O'Mahony S, Kelly JP, Soõs K, Törà I, Penke B, et al,. (1998). β-Amyloid(Phe(SO3H)24)25-35 in rat nucleus basalis induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation. Behav Brain Res 90: 133-145. (Pubitemid 28080555)
59. Harkany T, Abrahám I, Timmerman W, Laskay G, Tõth B, Sasvári M, et al,. (2000). β-Amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 12: 2735-2745.
60. Hauss-Wegrzyniak B, Dobrzanski P, Stoehr JD, Wenk GL, (1998). Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain Res 780: 294-303. (Pubitemid 28082916)
61. He Y, Yao Z, Gu Y, Kuang G, Chen Y, (1992). Nerve growth factor promotes collateral sprouting of cholinergic fibers in the septohippocampal cholinergic system of aged rats with fimbria transection. Brain Res 586: 27-35.
62. Head E, Moffat K, Das P, Sarsoza F, Poon WW, Landsberg G, et al,. (2005). β-amyloid deposition and tau phosphorylation in clinically characterized aged cats. Neurobiol Aging 26: 749-763. (Pubitemid 40228766)
63. Hong CS, Goins WF, Goss JR, Burton EA, Glorioso JC, (2006). Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther 13: 1068-1079.
64. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al,. (1996). Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274: 99-102. (Pubitemid 26332733)
65. Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y, (2004). Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. Proc Natl Acad Sci U S A 101: 6623-6628. (Pubitemid 38586024)
66. Imbimbo BP, Del Giudice E, Colavito D, D'Arrigo A, Dalle Carbonare M, Villetti G, et al,. (2007). 1-(3â,4â-Dichloro-2-fluoro[1,1â- biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 323: 822-830. (Pubitemid 350146064)
67. Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM, et al,. (2009). Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol 19: 636-647.
68. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, et al,. (2002). Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34: 509-519. (Pubitemid 34628749)
69. Kimura N, Tanemura K, Nakamura S, Takashima A, Ono F, Sakakibara I, et al,. (2003). Age-related changes of Alzheimer's disease-associated proteins in cynomolgus monkey brains. Biochem Biophys Res Commun 310: 303-311. (Pubitemid 37163664)
70. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD, (2003). Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A 100: 9980-9985. (Pubitemid 37087054)
71. Kumar VB, Farr SA, Flood JF, Kamlesh V, Franko M, Banks WA, et al,. (2000). Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides 21: 1769-1775. (Pubitemid 32058851)
72. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al,. (2004). Synaptic targeting by Alzheimer's related amyloid β oligomers. J Neurosci 24: 10191-10200. (Pubitemid 39492046)
73. Lane MA, (2000). Nonhuman primate models in biogerontology. Exp Gerontol 35: 533-541.
74. Lawlor PA, Young D, (2010). Aβ infusion and related models of Alzheimer dementia. In:, De Deyn PP, Van Dam D, (eds). Animal Models of Dementia. Springer Science + Business Media: New York, pp. 347-370.
75. Lawlor PA, Bland RJ, Das P, Price RW, Holloway V, Smithson L, et al,. (2007). Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Mol Neurodegener 2: 11.
76. Lee JA, Cole GJ, (2007). Generation of transgenic zebrafish expressing green fluorescent protein under control of zebrafish amyloid precursor protein gene regulatory elements. Zebrafish 4: 277-286. (Pubitemid 351282117)
77. Leimer U, Lun K, Romig H, Walter J, Grünberg J, Brand M, et al,. (1999). Zebrafish (Danio rerio) presenilin promotes aberrant amyloid beta-peptide production and requires a critical aspartate residue for its function in amyloidogenesis. Biochemistry 38: 13602-13609.
78. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, et al,. (2004). Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 165: 283-297. (Pubitemid 38821835)
79. Lemere CA, Oh J, Stanish HA, Peng Y, Pepivani I, Fagan AM, et al,. (2008). Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer's disease? Rejuvenation Res 11: 321-332. (Pubitemid 351601183)
80. Leroy K, Ando K, Héraud C, Yilmaz Z, Authelet M, Boeynaems JM, et al,. (2010). Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis 19: 705-719.
81. Lescaudron L, Stein DG, (1999). Differences in memory impairment and response to GM1 ganglioside treatment following electrolytic or ibotenic acid lesions of the nucleus basalis magnocellularis. Restor Neurol Neurosci 15: 25-37. (Pubitemid 29484553)
82. Levin ED, Rose JE, McGurk SR, Butcher LL, (1990). Characterization of the cognitive effects of combined muscarinic and nicotinic blockade. Behav Neural Biol 53: 103-112. (Pubitemid 20111366)
83. Levitan D, Greenwald I, (1995). Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377: 351-354.
84. Li X, Greenwald I, (1997). HOP-1, a Caenorhabditis elegans presenilin, appears to be functionally redundant with SEL-12 presenilin and to facilitate LIN-12 and GLP-1 signaling. Proc Natl Acad Sci U S A 94: 12204-12209. (Pubitemid 27467867)
85. Li A, Xie Z, Dong Y, McKay KM, McKee ML, Tanzi RE, (2007). Isolation and characterization of the Drosophila ubiquilin ortholog dUbqln: in vivo interaction with early-onset Alzheimer disease genes. Hum Mol Genet 16: 2626-2639. (Pubitemid 47617729)
86. Link CD, (1995). Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A 92: 9368-9372.
87. Link CD, (2006). C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Exp Gerontol 41: 1007-1013. (Pubitemid 44821699)
88. Luo LQ, Martin-Morris LE, White K, (1990). Identification, secretion, and neural expression of APPL, a Drosophila protein similar to human amyloid protein precursor. J Neurosci 10: 3849-3861.
89. McGowan E, Eriksen J, Hutton M, (2006). A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 22: 281-289.
90. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, et al,. (2006). Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12: 801-808. (Pubitemid 44050070)
91. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al,. (2010). Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 7: 90.
92. Malviya M, Kumar YC, Asha D, Chandra JN, Subhash MN, Rangappa KS, (2008). Muscarinic receptor 1 agonist activity of novel N-arylthioureas substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models. Bioorg Med Chem 16: 7095-7101.
93. Martin EM, Wilson RS, Penn RD, Fox JH, Clasen RA, Savoy SM, (1987). Cortical biopsy results in Alzheimer's disease: correlation with cognitive deficits. Neurology 37: 1201-1204. (Pubitemid 17123452)
94. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, et al,. (2010). Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 176: 870-880.
95. Mesulam MM, Mufson EJ, Wainer BH, Levey AI, (1983). Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 10: 1185-1201. (Pubitemid 14178569)
96. Meunier J, Ieni J, Maurice T, (2006). The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 149: 998-1012. (Pubitemid 44950803)
97. Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I, et al,. (2007). An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25: 778-785. (Pubitemid 47052191)
98. Moens CB, Donn TM, Wolf-Saxon ER, Ma TP, (2008). Reverse genetics in zebrafish by TILLING. Brief Funct Genomic Proteomic 7: 454-459.
99. Moran PM, (1993). Differential effects of scopolamine and mecamylamine on working and reference memory in the rat. Pharmacol Biochem Behav 45: 533-538.
100. Mulder J, Harkany T, Czollner K, Cremers TI, Keijser JN, Nyakas C, et al,. (2005). Galantamine-induced behavioral recovery after sublethal excitotoxic lesions to the rat medial septum. Behav Brain Res 163: 33-41. (Pubitemid 40991719)
101. Musa A, Lehrach H, Russo VA, (2001). Distinct expression patterns of two zebrafish homologues of the human APP gene during embryonic development. Dev Genes Evol 211: 563-567. (Pubitemid 34023929)
102. Nag S, Yee BK, Tang F, (1999). Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of β-amyloid (1-40). Brain Res Bull 50: 251-262. (Pubitemid 29528358)
103. Nakamura S, Murayama N, Noshita T, Annoura H, Ohno T, (2001). Progressive brain dysfunction following intracerebroventricular infusion of β1-42-amyloid peptide. Brain Res 912: 128-136. (Pubitemid 32800666)
104. Ness DK, Boggs LN, Hepburn DL, Gitter B, Long GG, May PC, et al,. (2004). Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months. Neurobiol Aging 25 (Suppl. 2): S238-S239.
105. Nishida Y, Ito S, Ohtsuki S, Yamamoto N, Takahashi T, Iwata N, et al,. (2009). Depletion of vitamin E increases amyloid beta accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease. J Biol Chem 284: 33400-33408.
106. Nishimura H, Higuchi O, Tateshita K, Tomobe K, Okuma Y, Nomura Y, (2006). Antioxidative activity and ameliorative effects of memory impairment of sulfur-containing compounds in Allium species. Biofactors 26: 135-146. (Pubitemid 43979365)
107. Nordberg A, Nilsson-HÃ¥kansson L, Adem A, Hardy J, Alafuzoff I, Lai Z, et al,. (1989). The role of nicotinic receptors in the pathophysiology of Alzheimer's disease. Prog Brain Res 79: 353-362. (Pubitemid 20047999)
108. Nornes S, Groth C, Camp E, Ey P, Lardelli M, (2003). Developmental control of Presenilin1 expression, endoproteolysis, and interaction in zebrafish embryos. Exp Cell Res 289: 124-132. (Pubitemid 36993842)
109. Nornes S, Newman M, Verdile G, Wells S, Stoick-Cooper CL, Tucker B, et al,. (2008). Interference with splicing of Presenilin transcripts has potent dominant negative effects on Presenilin activity. Hum Mol Genet 17: 402-412.
110. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM, (2003a). Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24: 1063-1070. (Pubitemid 37487883)
111. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al,. (2003b). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421. (Pubitemid 36937044)
112. Olariu A, Yamada K, Mamiya T, Hefco V, Nabeshima T, (2002). Memory impairment induced by chronic intracerebroventricular infusion of β-amyloid (1-40) involves downregulation of protein kinase C. Brain Res 957: 278-286. (Pubitemid 35356523)
113. Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE, et al,. (1995). Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 310: 970-973.
114. Paquet D, Bhat R, Sydow A, Mandelkow EM, Berg S, Hellberg S, et al,. (2009). A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest 119: 1382-1395.
115. Poon HF, Joshi G, Sultana R, Farr SA, Banks WA, Morley JE, et al,. (2004). Antisense directed at the Abeta region of APP decreases brain oxidative markers in aged senescence accelerated mice. Brain Res 1018: 86-96. (Pubitemid 38942865)
116. Poon HF, Farr SA, Thongboonkerd V, Lynn BC, Banks WA, Morley JE, et al,. (2005). Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochem Int 46: 159-168. (Pubitemid 41556623)
117. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A, (1987). Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 48: 9-15. (Pubitemid 17091427)
118. Ribé EM, Pérez M, Puig B, Gich I, Lim F, Cuadrado M, et al,. (2005). Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis 20: 814-822. (Pubitemid 41619357)
119. Riekkinen P Jr, Sirviö J, Aaltonen M, Riekkinen P, (1990). Effects of concurrent manipulations of nicotinic and muscarinic receptors on spatial and passive avoidance learning. Pharmacol Biochem Behav 37: 405-410.
120. Roertgen KE, Parisi JE, Clark HB, Barnes DL, O'Brien TD, Johnson KH, (1996). A beta-associated cerebral angiopathy and senile plaques with neurofibrillary tangles and cerebral hemorrhage in an aged wolverine (Gulo gulo). Neurobiol Aging 17: 243-247. (Pubitemid 26167635)
121. Rofina JE, van Ederen AM, Toussaint MJ, SecrÃve M, van der Spek A, van der Meer I, et al,. (2006). Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease. Brain Res 1069: 216-226. (Pubitemid 43145916)
122. Rosen DR, Martin-Morris L, Luo LQ, White K, (1989). A Drosophila gene encoding a protein resembling the human beta-amyloid protein precursor. Proc Natl Acad Sci U S A 86: 2478-2482. (Pubitemid 19102532)
123. Rush DK, (1988). Scopolamine amnesia of passive avoidance: a deficit of information acquisition. Behav Neural Biol 50: 255-274.
124. Sani S, Traul D, Klink A, Niaraki N, Gonzalo-Ruiz A, Wu CK, et al,. (2003). Distribution, progression and chemical composition of cortical amyloid-β deposits in aged rhesus monkeys: similarities to the human. Acta Neuropathol 105: 145-156. (Pubitemid 36798800)
125. Sarasa M, Pesini P, (2009). Natural non-transgenic animal models for research in Alzheimer's disease. Curr Alzheimer Res 6: 171-178.
126. Selden NR, Gitelman DR, Salamon-Murayama N, Parrish TB, Mesulam MM, (1998). Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 121: 2249-2257. (Pubitemid 28552464)
127. Selkoe DJ, (2000). Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 924: 17-25. (Pubitemid 32050177)
128. Sergeant N, Buée L, (2010). TAU models. In:, De Deyn PP, Van Dam D, (eds). Animal Models of Dementia. Springer Science + Business Media: New York, pp. 449-468.
129. Sherman KA, Friedman E, (1990). Pre- and post-synaptic cholinergic dysfunction in aged rodent brain regions: new findings and an interpretive review. Int J Dev Neurosci 8: 689-708.
130. Shih PH, Chan YC, Liao JW, Wang MF, Yen GC, (2010). Antioxidant and cognitive promotion effects of anthocyanin-rich mulberry (Morus atropurpurea L.) on senescence-accelerated mice and prevention of Alzheimer's disease. J Nutr Biochem 21: 598-605.
131. Shulman JM, Feany MB, (2003). Genetic modifiers of tauopathy in Drosophila. Genetics 165: 1233-1242. (Pubitemid 38020245)
132. Sipos E, Kurunczi A, Kasza A, Horváth J, Felszeghy K, Laroche S, et al,. (2007). Beta-amyloid pathology in the entorhinal cortex of rats induces memory deficits: implications for Alzheimer's disease. Neuroscience 147: 28-36. (Pubitemid 46881105)
133. Sloan HL, Good M, Dunnett SB, (2006). Double dissociation between hippocampal and prefrontal lesions on an operant delayed matching task and a water maze reference memory task. Behav Brain Res 171: 116-126. (Pubitemid 43728403)
134. Sowell RA, Butterfield DA, (2010). Spontaneous vertebrate models of Alzheimer Dementia: Selectively bred strains (SAM strains). In:, De Deyn PP, Van Dam D, (eds). Animal Models of Dementia. Springer Science + Business Media: New York, pp. 271-293.
135. Staufenbiel M, Wiederhold KH, Tissot AC, Frey P, Fulurija A, Hiestand P, et al,. (2006). Immunization with Aβ1-6 coupled to the virus-like particle Qβ (CAD106) efficiently removes β-amyloid without inducing Aβ-reactive T-cells. Proceedings of 10th ICAD Alzheimer's and Dementia 2 (Suppl. 1), S20.
136. Stürchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al,. (1997). Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94: 13287-13292. (Pubitemid 27518514)
137. Sunderland T, Tariot PN, Weingartner H, Murphy DL, Newhouse PA, Mueller EA, et al,. (1986). Pharmacologic modelling of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 10: 599-610.
138. Sy M, Kitazawa M, LaFerla F, (2010). The 3xTg-AD Mouse Model: Reproducing and modulating plaque and tangle pathology. In:, De Deyn PP, Van Dam D, (eds). Animal Models of Dementia. Springer Science + Business Media: New York, pp. 482-496.
139. Szabados T, Dul C, Majtényi K, Hargitai J, Pénzes Z, Urbanics R, (2004). A chronic Alzheimer's model evoked by mitochondrial poison sodium azide for pharmacological investigations. Behav Brain Res 154: 31-40. (Pubitemid 39070450)
140. Tajes M, Gutierrez-Cuesta J, Folch J, Ortuño-Sahagun D, Verdaguer E, Jiménez A, et al,. (2010). Neuroprotective role of intermittent fasting in senescence-accelerated mice P8 (SAMP8). Exp Gerontol 45: 702-710.
141. Takeda T, (1999). Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiol Aging 20: 105-110. (Pubitemid 29488720)
142. Tekirian TL, Cole GM, Russell MJ, Yang F, Wekstein DR, Patel E, et al,. (1996). Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains. Neurobiol Aging 17: 249-257. (Pubitemid 26167636)
143. Toledana A, Ãlvarez MI, (2010). Lesion-induced vertebrate models of Alzheimer dementia. In:, De Deyn PP, Van Dam D, (eds). Animal Models of Dementia. Springer Science + Business Media: New York, pp. 295-345.
144. Tomasiewicz HG, Flaherty DB, Soria JP, Wood JG, (2002). Transgenic zebrafish model of neurodegeneration. J Neurosci Res 70: 734-745. (Pubitemid 35416890)
145. Trabace L, Cassano T, Steardo L, Pietra C, Villetti G, Kendrick KM, et al,. (2000). Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. J Pharmacol Exp Ther 294: 187-194. (Pubitemid 30434686)
146. Tse FL, Laplanche R, (1998). Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. Pharm Res 15: 1614-1620. (Pubitemid 28465750)
147. Uchida K, Yoshino T, Yamaguchi R, Tateyama S, Kimoto Y, Nakayama H, et al,. (1995). Senile plaques and other senile changes in the brain of an American black bear. Vet Pathol 32: 412-414.
148. Vale-Martínez A, Guillazo-Blanch G, Martí-Nicolovius M, Nadal R, Arévalo-García R, Morgado-Bernal I, (2002). Electrolytic and ibotenic acid lesions of the nucleus basalis magnocellularis interrupt long-term retention, but not acquisition of two-way active avoidance, in rats. Exp Brain Res 142: 52-66. (Pubitemid 34028240)
149. Van Dam D, De Deyn PP, (2006). Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5: 956-970. (Pubitemid 44660608)
150. Van Dam D, De Deyn PP, (2010). The APP23 mouse model for Alzheimer's disease. In:, De Deyn PP, Van Dam D, (eds). Animal Models of Dementia. Springer Science + Business Media: New York, pp. 399-413.
151. Van Dam D, Vloeberghs E, Abramowski D, Staufenbiel M, De Deyn PP, (2005). APP23 mice as a model of Alzheimer's disease: an example of a transgenic approach to modeling a CNS disorder. CNS Spectr 10: 207-222. (Pubitemid 40489290)
152. Van Dam D, Coen K, De Deyn PP, (2010). Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. J Psychopharmacol 24: 383-388.
153. Vickers JC, Dickson TC, Adlard PA, Saunders HL, King CE, McCormack G, (2000). The cause of neuronal degeneration in Alzheimer's disease. Prog Neurobiol 60: 139-165.
154. Vloeberghs E, Van Dam D, Engelborghs S, Nagels G, Staufenbiel M, De Deyn PP, (2004). Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur J Neurosci 20: 2757-2766. (Pubitemid 39573791)
155. Vloeberghs E, Van Dam D, Coen K, Staufenbiel M, De Deyn PP, (2006). Aggressive male APP23 mice modeling behavioral alterations in dementia. Behav Neurosci 120: 1380-1383. (Pubitemid 46058713)
156. Vloeberghs E, Coen K, Van Dam D, De Deyn PP, (2008). Validation of the APP23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviour. Arzneimittelforschung 58: 265-268. (Pubitemid 351961810)
157. Voytko ML, Tinkler GP, (2004). Cognitive function and its neural mechanisms in nonhuman primate models of aging, Alzheimer disease, and menopause. Front Biosci 9: 1899-1914. (Pubitemid 38918640)
158. Walsh DM, Selkoe DJ, (2007). A beta oligomers-a decade of discovery. J Neurochem 101: 1172-1184.
159. Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, et al,. (1998). Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 18: 2161-2173. (Pubitemid 28141421)
160. Wenk GL, McGann K, Hauss-Wegrzyniak B, Rosi S, (2003). The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease. Neuroscience 121: 719-729. (Pubitemid 38367510)
161. Whitehouse PJ, Au KS, (1986). Cholinergic receptors in aging and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 10: 665-676. (Pubitemid 17172651)
162. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR, (1982). Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10: 122-126. (Pubitemid 11053099)
163. Willemsen R, van't Padje S, van Swieten JC, Oostra BA, (2010). Zebrafish (Danio rerio) as a models organism for dementia. In:, De Deyn PP, Van Dam D, (eds). Animal Models of Dementia. Springer Science + Business Media: New York, pp. 255-269.
164. Wimo A, Winblad B, Aguero-Torres H, von Strauss E, (2003). The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 17: 63-67. (Pubitemid 36736838)
165. Wimo A, Winblad B, Jönsson L, (2010). The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 6: 98-103.
166. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, et al,. (2001). Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293: 711-714. (Pubitemid 32728676)
167. Wong KK, Ho MT, Lin HQ, Lau KF, Rudd JA, Chung RC, et al,. (2010). Cryptotanshinone, an acetylcholinesterase inhibitor from Salvia miltiorrhiza, ameliorates scopolamine-induced amnesia in Morris water maze task. Planta Med 76: 228-234.
168. Wu X, Glinn MA, Ostrowski NL, Su Y, Ni B, Cole HW, et al,. (1999). Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res 847: 98-104. (Pubitemid 29516710)
169. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, et al,. (2006). Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26: 13102-13113. (Pubitemid 44954628)
170. Yagi H, Katoh S, Akiguchi I, Takeda T, (1988). Age-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory. Brain Res 474: 86-93. (Pubitemid 19001185)
171. Yamada M, Chiba T, Sasabe J, Nawa M, Tajima H, Niikura T, et al,. (2005). Implanted cannula-mediated repetitive administration of Aβ25-35 into the mouse cerebral ventricle effectively impairs spatial working memory. Behav Brain Res 164: 139-146. (Pubitemid 41337867)
172. Zhong H, Zou H, Semenov MV, Moshinsky D, He X, Huang H, et al,. (2009). Characterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling. Mol Biosyst 5: 1356-1360.
173. Zou H, Zhou L, Li Y, Cui Y, Zhong H, Pan Z, et al,. (2010). Benzo[e]isoindole-1,3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). Synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode. J Med Chem 53: 994-1003.